RBC names Gilead a top biotech pick based on valuation

Investing

A scientist at Gilead Sciences analyzes patient antibody levels at the Gilead laboratory in Foster City, Calif.

David Paul Morris | Bloomberg | Getty Images

Now is a good entry point into Gilead’s stock as the company begins to stabilize, while still trading at a discount to its peers, according to RBC Capital Markets.

The firm named biotechnology company Gilead to its top picks list and maintained its $91 price target, a near 34% upside.

Products You May Like

Articles You May Like

Warren Buffett’s Berkshire Hathaway reveals insurer Chubb as confidential stock it’s been buying
Netflix ad-supported tier has 40 million monthly users, nearly double previous count
Walgreens to offer its own cheaper version of opioid overdose reversal drug naloxone
Alibaba shares fall 6% after the Chinese tech giant posts 86% drop in profit
Shares of Cartier owner Richemont climb on record full-year sales, new CEO

Leave a Reply

Your email address will not be published. Required fields are marked *